Joseph P. Lyssikatos - 29 Apr 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF SCIENTIFIC OFFICER, Director
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
29 Apr 2024
Net transactions value
-$201,548
Form type
4
Filing time
01 May 2024, 19:04:07 UTC
Previous filing
15 Apr 2024
Next filing
31 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $13,440 +12,000 $1.12* 12,000 29 Apr 2024 Direct F1
transaction ELVN Common Stock Sale $196,265 -10,987 -92% $17.86 1,013 29 Apr 2024 Direct F1, F2
transaction ELVN Common Stock Sale $18,723 -1,013 -100% $18.48 0 29 Apr 2024 Direct F1, F3
holding ELVN Common Stock 1,117,035 29 Apr 2024 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -12,000 -5.2% $0.000000 218,550 29 Apr 2024 Common Stock 12,000 $1.12 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $17.369 to $18.3544. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $18.37 to $18.5795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
F5 All of the shares subject to this option are fully vested and exercisable as of the date hereof.